JP2018538000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538000A5 JP2018538000A5 JP2018533097A JP2018533097A JP2018538000A5 JP 2018538000 A5 JP2018538000 A5 JP 2018538000A5 JP 2018533097 A JP2018533097 A JP 2018533097A JP 2018533097 A JP2018533097 A JP 2018533097A JP 2018538000 A5 JP2018538000 A5 JP 2018538000A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- human
- recombinant
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003527 eukaryotic cell Anatomy 0.000 claims 20
- 238000000034 method Methods 0.000 claims 15
- 210000000349 chromosome Anatomy 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 10
- 230000007017 scission Effects 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000002459 blastocyst Anatomy 0.000 claims 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000013607 AAV vector Substances 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000006780 non-homologous end joining Effects 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031458A JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387318P | 2015-12-23 | 2015-12-23 | |
| US62/387,318 | 2015-12-23 | ||
| US201662416513P | 2016-11-02 | 2016-11-02 | |
| US62/416,513 | 2016-11-02 | ||
| PCT/US2016/068289 WO2017112859A1 (en) | 2015-12-23 | 2016-12-22 | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031458A Division JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538000A JP2018538000A (ja) | 2018-12-27 |
| JP2018538000A5 true JP2018538000A5 (enExample) | 2020-02-06 |
| JP6846429B2 JP6846429B2 (ja) | 2021-03-24 |
Family
ID=57794384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533097A Active JP6846429B2 (ja) | 2015-12-23 | 2016-12-22 | ヒトβ−２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2021031458A Active JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A Pending JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031458A Active JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A Pending JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190017075A1 (enExample) |
| EP (2) | EP3988655A3 (enExample) |
| JP (3) | JP6846429B2 (enExample) |
| AU (2) | AU2016379393B2 (enExample) |
| CA (1) | CA3009637A1 (enExample) |
| ES (1) | ES2901000T3 (enExample) |
| WO (1) | WO2017112859A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| US20190017075A1 (en) * | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| KR20230010826A (ko) * | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| JP7170666B2 (ja) * | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ，インク． | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| EP4775669A2 (en) | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| TW201923073A (zh) * | 2017-11-20 | 2019-06-16 | 新加坡商泰莎治療私人有限公司 | 經修飾之k562細胞 |
| CA3082204A1 (en) * | 2017-12-13 | 2019-06-20 | Janssen Biotech, Inc. | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102617818B1 (ko) * | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| WO2020146807A1 (en) * | 2019-01-10 | 2020-07-16 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified transferrin gene |
| EP4332115A3 (en) | 2019-04-03 | 2024-05-29 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| EP3947646A1 (en) | 2019-04-05 | 2022-02-09 | Precision BioSciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN114026228A (zh) | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | 用于识别序列的工程化大范围核酸酶的优化 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| US20240011003A1 (en) * | 2020-08-21 | 2024-01-11 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| JP2023543361A (ja) * | 2020-09-29 | 2023-10-13 | ニューエクセル・セラピューティクス・インコーポレイテッド | Ｎｅｕｒｏｄ１及びｄｌｘ２ベクター |
| EP4221761A4 (en) * | 2020-09-29 | 2025-02-26 | Neuexcell Therapeutics Inc. | Neurod1 combination vector |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022112596A1 (en) * | 2020-11-30 | 2022-06-02 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| AU2022368911A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| WO2026047626A1 (en) | 2024-08-30 | 2026-03-05 | Inceptor Bio, Llc | Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| EP2329017A2 (en) * | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| EP3683319A1 (en) * | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| US20190017075A1 (en) | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
-
2016
- 2016-12-22 US US16/065,756 patent/US20190017075A1/en not_active Abandoned
- 2016-12-22 CA CA3009637A patent/CA3009637A1/en active Pending
- 2016-12-22 ES ES16825979T patent/ES2901000T3/es active Active
- 2016-12-22 AU AU2016379393A patent/AU2016379393B2/en active Active
- 2016-12-22 WO PCT/US2016/068289 patent/WO2017112859A1/en not_active Ceased
- 2016-12-22 EP EP21193857.6A patent/EP3988655A3/en not_active Withdrawn
- 2016-12-22 EP EP16825979.4A patent/EP3394253B1/en active Active
- 2016-12-22 JP JP2018533097A patent/JP6846429B2/ja active Active
-
2020
- 2020-10-19 US US17/074,135 patent/US20210032664A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031458A patent/JP7203873B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209145A patent/JP2023052095A/ja active Pending
-
2023
- 2023-04-03 AU AU2023202035A patent/AU2023202035A1/en not_active Abandoned
- 2023-10-20 US US18/491,484 patent/US20240052373A1/en not_active Abandoned
-
2025
- 2025-09-03 US US19/317,909 patent/US20260201422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520800A5 (enExample) | ||
| Sandoval-Villegas et al. | Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering | |
| US10858662B2 (en) | Genome editing with split Cas9 expressed from two vectors | |
| IL277883B2 (en) | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene | |
| US20210301301A1 (en) | Targeted modification of rat genome | |
| RU2645475C2 (ru) | Опосредованное нуклеазой нацеливание с большими нацеливающими векторами | |
| KR102658529B1 (ko) | 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물 | |
| ES2784754T3 (es) | Métodos y composiciones para modificar un locus objetivo | |
| JP2018536390A5 (enExample) | ||
| NZ773169A (en) | Universal donor cells | |
| Mizuno-Iijima et al. | Efficient production of large deletion and gene fragment knock-in mice mediated by genome editing with Cas9-mouse Cdt1 in mouse zygotes | |
| JP2021502085A5 (enExample) | ||
| IL274179B2 (en) | Targeted replacement of endogenous T cell receptors | |
| JP2011501971A5 (enExample) | ||
| JP2017513479A5 (enExample) | ||
| IL309801A (en) | Use of protein domains interacting with the nucleosome to enhance targeted genome modification | |
| JP2012522501A5 (enExample) | ||
| JP2018520648A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2016518142A5 (enExample) | ||
| JP2018531624A5 (enExample) | ||
| JP2018525979A5 (enExample) | ||
| CN108690845A (zh) | 基因组编辑系统和方法 | |
| HRP20201443T1 (hr) | Postupci i pripravci za liječenje genetskog stanja |